Geographic disparities in cancer treatment are often assumed to reflect patient preference or tumor biology — but when survival outcomes diverge along regional lines, the implication is that where a patient lives shapes whether she lives. That possibility now has rigorous population-level evidence behind it, with meaningful consequences for how equitable oncology care is evaluated.
Analyzing 61,935 Swedish women diagnosed with HR+/HER2- early breast cancer between 2007 and 2023 — the most common breast cancer subtype — researchers found that chemotherapy use varied from 23.0% to 34.7% across Sweden's healthcare regions. Overall, 28% of patients received chemotherapy. Younger age, larger tumors, lymph node involvement, and higher tumor grade predicted chemotherapy administration. Crucially, after adjusting for clinicopathological and socioeconomic variables, the region with the highest chemotherapy utilization posted the lowest 10-year all-cause mortality. These regional survival differences were most pronounced among women aged 65 and older, while younger patients showed minimal geographic variation in outcomes.
This dataset, drawn from a nationally comprehensive quality registry with 16 years of follow-up, carries unusual statistical authority. Most prior studies linking chemotherapy variation to outcomes have been smaller or more regionally constrained. The finding that socioeconomic factors did not explain the regional survival gaps is particularly notable — it redirects attention toward institutional protocols, oncologist decision-making culture, and access to genomic risk tools like Oncotype DX or Prosigna, which can clarify chemotherapy benefit in borderline-risk HR+/HER2- disease. The age stratification adds nuance: older women, who face greater chemotherapy toxicity trade-offs and whose treatment decisions are more discretionary, appear most vulnerable to under-treatment in lower-utilization regions. This observational cohort cannot fully resolve causality — confounding by unmeasured tumor characteristics remains possible — but the magnitude and consistency of the effect across a universal healthcare system makes practice variation the most parsimonious explanation. The findings should accelerate harmonization of clinical decision frameworks across Swedish regions and likely have implications for similarly structured national health systems globally.